GlassScriptPhysician profile
Venu Prabaker
NPI 1467401042
$14,857.49
in general payments reported to CMS, 2019-2025
54 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,816 · 2020: $2,034 · 2021: $3,975 · 2022: $4,014 · 2023: $681 · 2024: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,680.56 | 2019-2023 | Wegovy, Saxenda |
| Amgen INC. | $1,544.66 | 2019-2023 | Repatha, Otezla |
| Abbvie INC. | $1,016.62 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $914.09 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $846.05 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $805.01 | 2019-2024 | |
| Esperion Therapeutics, INC. | $691.00 | 2020-2023 | Nexletol |
| Lilly USA, LLC | $575.33 | 2019-2023 | Jardiance, Emgality |
| Amarin Pharma, INC. | $523.42 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $517.17 | 2021-2022 | |
| Radius Health, INC. | $512.46 | 2019-2023 | |
| Boston Scientific Corporation | $334.35 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $318.55 | 2020-2021 | |
| Pfizer INC. | $293.61 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $287.51 | 2022 |
Show all 53 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Venu Prabaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.